Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Collegium Pharmaceutical announced financial results for the quarter ended September 30, 2026.
COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Collegium Pharmaceutical announced financial results for the quarter ended September 30, 2026
- Full quarterly results and management commentary are contained in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Collegium released an earnings presentation on November 5, 2026
- Presentation contains the company’s latest earnings-related information and investor messaging
- Exhibit 99.2 provides the substantive financial and operational details for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue reached a record $216.3M, up 3% year over year, while adjusted EBITDA declined 9% to $121.6M
- JORNAY PM revenue rose 24% to $51.9M, with prescriptions up 16% and prescribers up 19% to nearly 33,000
- AZSTARYS generated $26.5M in its first full Collegium-owned quarter, with prescriptions up nearly 2% year over year
- Pain portfolio revenue fell 18% to $138.0M, driven by Nucynta Franchise revenue declining 44% to $30.8M
- 2026 guidance reaffirmed: product revenue $825M-$855M and adjusted EBITDA $445M-$470M, alongside a planned $50M share repurchase before year-end
Item EX-99.2 · Exhibit EX-99.2
- Q3’26 product revenue $216M, up 3% YoY, while adjusted EBITDA fell 9% to $122M on higher adjusted operating expenses
- 2026 guidance maintained: product revenue $825–855M, adjusted EBITDA $445–470M
- ADHD expansion gaining traction: JORNAY PM revenue $190–200M guided, AZSTARYS revenue $65–75M after May acquisition
- AZSTARYS quarterly prescriptions rose 2% to 190K, with patent protection through 2037
- Capital returns continue: $50M accelerated share repurchase, with $100M remaining under authorization through December 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings
Get the next COLL 8-K as it lands
Follow COLL for push alerts, or ask the research agent what this filing means.